On Thursday, Shares of Ventas, Inc. (NYSE:VTR), gained 1.62% to $57.01.
Ventas declared senior vice president promotions in its asset administration business. These changes became effective on August 17, 2015 and were made in connection with the executive administration realignment of roles and responsibilities that were formerly declared as part of Ventas’s spin-off of Care Capital Properties, Inc. (CCP).
Christian N. Cummings has been promoted to Senior Vice President of Asset Administration focusing on Ventas’s seniors housing operating portfolio (SHOP) and enterprise wide dispositions, reporting to Executive Vice President and Chief Financial Officer Bob Probst, who has assumed responsibility for our SHOP business. Chris joined Ventas in 2002 as an analyst and has held various roles of increasing responsibility since then. Most recently he was Vice President of Asset Administration, a position he has held since 2007. He earned his Master of Business Administration from the University of Louisville, where he also earned a Bachelor of Arts in history.
Nicholas W. Jacoby, has been promoted to Senior Vice President of Asset Administration focusing on Ventas’s triple net leased assets, reporting to Executive Vice President, Chief Administrative Officer and General Counsel T. Richard Riney, who has assumed responsibility for the Company’s triple net lease business. Since 2012 Nick has been a Vice President of Asset Administration. Nick joined the Company in 2005 as a financial analyst and has held various roles of increasing responsibility since then. Nick earned both a Master of Business Administration and a Bachelor of Science in business administration with a focus in accounting, from the University of Louisville.
Ventas, Inc. is a publicly owned real estate investment trust. The firm engages in investment, administration, financing, and leasing of properties in the healthcare industry. It invests in the real estate markets of the United States and Canada.
Shares of Caesars Entertainment Corp (NASDAQ:CZR), inclined 3.02% to $8.71, during its last trading session.
Caesars Entertainment Corporation and Caesars Entertainment Operating Company have reached a Bank Restructuring Support Agreement (“Bank RSA”).
The agreement, which is effective right away, secures the support of CEOC’s largest and most senior creditor constituencies and represents a key milestone in Caesars Entertainment and CEOC’s efforts to implement a consensual restructuring of CEOC. CEOC’s restructuring is now supported by CEOC’s First Lien Bank Lenders and First Lien Bondholders, which represent the most senior $12 billion of CEOC’s capital structure.
Caesars Entertainment and CEOC continue to engage in talk aboutions with junior creditors to build additional support for the formerly declared Second Lien Restructuring Agreement in an effort to complete the restructuring consensually. However, the senior creditors’ support of today’s agreement paves the way toward a confirmable plan for the restructuring of CEOC.
Caesars Entertainment Corporation, through its auxiliaries, provides casino-entertainment and hospitality services in the United States and internationally. It operates in four segments: Caesars Entertainment Resort Properties, Caesars Growth Partners Casino Properties and Developments, Caesars Interactive Entertainment, and Caesars Entertainment Operating Company.
At the end of Thursday’s trade, Shares of Eli Lilly and Co (NYSE:LLY), gained 3.26% to $83.74.
Eli Lilly and Company will attend the Morgan Stanley Global Healthcare Conference on Thursday, September 17, 2015. Sue Mahony, Ph.D., senior vice president and president of Lilly Oncology and Richard Gaynor, M.D., senior vice president of product development and medical affairs for Lilly Oncology, will take part in a fireside chat at 3:30 p.m., Eastern Daylight Time.
Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. It operates through two segments, Human Pharmaceutical Products and Animal Health Products.
Finally, Amgen, Inc. (NASDAQ:AMGN), ended its last trade with 1.13% gain, and closed at $155.72.
Amgen, declared that the U.S. Food and Drug Administration (FDA) has approved a new cholesterol-lowering medication, Repatha™ (evolocumab) Injection. Repatha is a human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that reduces the liver’s ability to remove low-density lipoprotein cholesterol (LDL-C), or “bad” cholesterol, from the blood.1 Repatha is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD), who require additional lowering of LDL-C; and as an adjunct to diet and other LDL-lowering therapies for the treatment of patients with homozygous familial hypercholesterolemia (HoFH), who require additional lowering of LDL-C. The effect of Repatha on cardiovascular morbidity and mortality has not been determined.
“We are excited about today’s approval of Repatha in the U.S. as patients and physicians will now have a new treatment option to lower LDL cholesterol,” said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. “Data from key clinical studies have shown that Repatha significantly reduces LDL cholesterol in patients who have not been able to lower their LDL cholesterol through diet and statins alone. At Amgen, we are committed to improving the lives of patients and are inspired by the potential for Repatha to aid in the global fight against one of the major risk factors for cardiovascular disease.”
Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses for the treatment of illness in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
